Glivec and Tarceva Patent Cases Failed Because Evidence Of Efficacy Overlooked – IP Attorney
This article was originally published in PharmAsia News
Executive Summary
Despite industry criticism of India's patent enforcement system, recent IP cases, such as the Tarceva and Glivec cases, have demonstrated India's High Courts' ability to enforce judgments and reach well-reasoned conclusions with relative speed, according to Schiff Hardin attorney Christopher Ohly
You may also be interested in...
Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs
NEW DELHI - India, along with China, is increasingly becoming a popular destination for pharmaceutical research and development outsourced from the West, and more multinational companies are partnering with Indian CROs to improve productivity, cut costs and bring more drugs to market faster
Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs
NEW DELHI - India, along with China, is increasingly becoming a popular destination for pharmaceutical research and development outsourced from the West, and more multinational companies are partnering with Indian CROs to improve productivity, cut costs and bring more drugs to market faster
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)
Novartis' Head of Corporate Research Paul Herrling and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, sat down recently with PharmAsia News on the sidelines of the China 2008 Pharmaceutical R&D Summit in Shanghai to discuss Novartis' R&D plans in China and the Pacific Rim.